Benzinga's Top Pre-Market Losers

Spectrum Pharmaceuticals

dipped 35.40% to $8.03 in the pre-market session. Spectrum Pharmaceuticals expects sales of its drug Fusilev in the range of $10 million to $15 million for the first quarter and $80 million to $90 million for the year. Velti plc

fell 26.05% to $2.30 in the pre-market session. Velti posted a loss of $5.18 million in the fourth quarter. PulteGroup

tumbled 5.82% to $18.60 in the pre-market trading. PulteGroup's trailing-twelve-month ROA is 2.17%. Mellanox Technologies

moved down 4.32% to $62.72 in the pre-market session. Mellanox shares have jumped 72.73% over the past 52 weeks, while the S&P 500 index has gained 11.21% in the same period.